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Abstract
Background
Lower gastrointestinal (GI) symptoms are poor predictors of colorectal cancer (CRC).  This study 
examined the diagnostic yield of colonoscopy by faecal haemoglobin concentration (f-Hb) in 
symptomatic patients assessed in primary care by faecal immunochemical testing (FIT). 
Methods
In three Scottish NHS Boards, FIT kits (HM-JACKarc, Hitachi Chemical Diagnostics Systems 
Co., Ltd, Tokyo, Japan) were used by GPs to guide referrals for patients with lower GI symptoms 
(lab data studied for 12 months from December 2015 onward in Tayside, 18 months from June 
2018 onward in Fife, and 5 months from September 2018 onward in Greater Glasgow and Clyde).  
CRC cases diagnosed at colonoscopy were ascertained from colonoscopy and pathology records.
Results
4841 symptomatic patients who underwent colonoscopy after FIT submission were included.  Of 
2166 patients (44.7%) with f-Hb <10 µg Hb/g faeces (µg/g), 14 (0.6%) were diagnosed with CRC, 
with a number needed to scope (NNS) of 155.  Of 2675 patients (55.3%) with f-Hb ≥10 µg/g, 252 
were diagnosed with CRC (9.4%) with a NNS of 11.  Of 705 patients with f-Hb ≥400 µg/g, 158 
(22.4%) were diagnosed with CRC with a NNS of 5.  Over half of those diagnosed with CRC with 
f-Hb <10 µg/g had co-existing anaemia.
Conclusions
Symptomatic patients with f-Hb ≥10 µg/g should undergo further investigation  for CRC, while 
higher f-Hb could be used to triage its urgency during the COVID-19 recovery phase.  Patients 
with f-Hb <10 µg/g, without anaemia, are very unlikely to be diagnosed with CRC and the 
majority need no further investigation.A
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What does this add to the literature?
This study of 4841 patients undergoing colonoscopy across three Scottish NHS Boards, concludes 
that reliance should not be placed on symptoms when deciding who to refer for colonoscopy. 
Symptoms should be regarded as an entry point to the diagnostic pathway and decision making 
should be guided by faecal haemoglobin.  
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Introduction
Both NHS Scotland and National Institute for Health and Care Excellence (NICE) guidance to 
general practitioners (GPs) suggest a variety of lower GI symptoms which should prompt either an 
urgent referral for an appointment within two weeks, or consideration of such a referral, varying 
with age and the additional presence of iron deficiency anaemia [1-2].  
Lower gastrointestinal (GI) symptoms are poor predictors of colorectal cancer (CRC) [3].  Indeed, 
most symptoms that can be present in patients with CRC and other significant bowel disease 
(SBD: higher-risk adenoma and inflammatory bowel disease), often reflect non-significant or 
functional bowel disorders [4-5].  Consequently, the introduction of the “urgent suspicion of 
cancer” (USC) referral  and “two week wait (2ww)” pathways in Scotland and England 
respectively led to a large increase in referrals but no change in stage of diagnosis of patients with 
CRC [6].   
NICE have also issued diagnostic guidance (DG30) regarding the use of faecal haemoglobin 
concentration (f-Hb) measured using a faecal immunochemical test (FIT) [7].  It is recommended 
that a f-Hb threshold of 10 µg Hb/g faeces (µg/g) be used to “guide” referral from primary care in 
patients without rectal bleeding, and who do not meet the criteria for a suspected cancer pathway 
per NICE (NG12) guidance. 
Prior to the COVID-19 pandemic, pressure on existing referral pathways and endoscopy capacity 
had led NICE to develop the above guidance, in which f-Hb would be used to guide referral of 
patients with symptoms [8].  Such guidance was given further support by several observational 
studies on symptomatic patients in the United Kingdom (UK) [9-11].  However, the current 
climate has seen significant curtailment of endoscopy activity across the UK, with many NHS 
Boards and Trusts initially ceasing activity entirely, and most now entering a period of “recovery” 
of activity [12-13].  Despite this, ongoing requirements for patient investigation, endoscopy suite 
decontamination and the existing backlog of participants with a positive screening test result, and 
symptomatic patients requiring colonoscopy, are likely to lead to greater pressures over the long 
term.  Therefore, the need for useful triage of patients with lower GI symptoms is even greater, 
and f-Hb has already been reported to be effective in this respect [14-16].   
**What is less clear is whether the symptomatic f-Hb threshold suggested in DG30 (10 µg/g) 
remains the most appropriate to guide referral for colonoscopy in symptomatic patients in the post-A
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COVID-19 recovery phase, including in those patients meeting NG12 referral criteria.  
Furthermore, a key question of the moment relates to the yield of CRC at higher f-Hb thresholds in 
light of guidance being issued by the British Society of Gastrointestinal and Abdominal Radiology 
(BSGAR, with acknowledgement of British Society of Gastroenterology [BSG]), for example, 
advocating urgent investigation in those with NG12 specified symptoms only for those with f-Hb 
>100 µg/g [17].  In contrast, the Scottish Government recommendations are to investigate all 
symptomatic patients with f-Hb ≥10 µg/g during the COVID 19 recovery phase, using the f-Hb 
concentration to determine the modality and urgency of further investigation [12].
Therefore, the aim of the present study was to examine the yield of CRC in patients who had 
undergone colonoscopy across three Scottish NHS Boards, having been referred from primary 
care with lower GI symptoms and having submitted a FIT at the time of referral.
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Patients and Methods
Patients:
In three Scottish NHS Boards (Tayside, Fife and Greater Glasgow and Clyde), a FIT kit with one 
specimen collection device (Hitachi Chemical Diagnostics Systems Co., Ltd, Tokyo, Japan), along 
with pictorial instructions for use and a return envelope, were made available to GP practices as an 
adjunct to clinical acumen and a full blood count to guide referral practice for all patients 
presenting with lower GI symptoms.  The period of data collection was between December 2015 – 
December 2016 (12 months) in Tayside, June 2018 - December 2019 (18 months) in Fife, and 
September 2018 – January 2019 (5 months) in Greater Glasgow and Clyde.  
In all three NHS Boards, patients were requested to collect a single faecal sample and to return the 
FIT kit as soon as possible to the GP surgery.  The kits were transported to the local departments 
of laboratory medicine at ambient temperature by means of the routine specimen collection 
services and then stored at 4°C prior to analysis.  Analyses were carried out from Monday to 
Friday, so that most samples were analysed on the day of receipt in the laboratory, and results 
were reported electronically to the requesting GP.  Samples collected in Tayside and Fife were 
analysed at Ninewells Hospital, Dundee, while samples collected in Greater Glasgow and Clyde 
were analysed at Stobhill Hospital, Glasgow. 
Only patients who had undergone colonoscopy as a result of a primary care referral with lower GI 
symptoms (including rectal bleeding), with an associated FIT result, were included.  All categories 
of urgency of referral were included.  Patients without a FIT result, who had undergone 
colonoscopy without submitting a previous FIT, had not undergone colonoscopy following a FIT 
or had been investigated by other methods such as CT colonography, were not included in the 
analysis.
Methods:
Faecal haemoglobin concentration (f-Hb) was measured using the HM-JACKarc (Hitachi 
Chemical Diagnostics Systems) analytical system in the two laboratories serving the three NHS 
Boards.  For f-Hb, this system has a limit of detection (LoD) of 2 μg/g, a limit of quantitation A
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(LoQ) of 7 μg/g and an upper measurement limit of 400 μg/g. Samples with results above the 
upper measurement limit were therefore reported as ≥ 400 μg/g, and results with f-Hb ≥ 10 μg/g 
were defined as “positive”, that is worthy of further investigation, as recommended in NICE DG30 
[7].  The reports also sign-posted GPs to advice that f-Hb < 10 μg/g, in the absence of iron 
deficiency anaemia (IDA), rectal bleeding, persistent diarrhoea, or a mass, suggests that SBD was 
extremely unlikely.
In this observational study, data on all FIT specimens received from primary care were retrieved 
from the laboratory databases of each NHS Board and manually linked using the patient’s unique 
identifier, the Community Health Index (CHI) number, with the NHS Boards’ electronic patient 
record to access all correspondence, laboratory results, referrals to secondary care, colonoscopy 
findings, hospital admissions and any subsequent attendance at the primary care out-of-hours 
(OOH) service.  Linkage was then performed with regional cancer registry and colorectal multi-
disciplinary team data to confirm CRC diagnoses and flag any potentially missed cancers. 
Caldicott Guardian and ethical approvals were in place from all three NHS Boards to safeguard 
the record linkage.  
Analysis:
The diagnostic yield of colonoscopy with respect to CRC was calculated in terms of 
predetermined f-Hb ranges and thresholds and summarised in terms of the number of 
colonoscopies required to diagnose one CRC, that is, the number needed to scope (NNS).  The 
details of patients diagnosed with CRC and f-Hb <10 µg/g were recorded and presented.
MedCalc statistical software (MedCalc Software, Mariakerke, Belgium) was used for all Tayside 
calculations, with Microsoft Excel (Microsoft, Microsoft Campus, Reading
UK) for Fife calculations, and SPSS v25 (IBM, NY, USA) used for Greater Glasgow and Clyde 
calculations. 
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Results
Patients
In total, 4841 patients were included, (Table 1).  Of these, 266 (5.5%) were diagnosed with CRC, 
giving a NNS of 19 for the entire cohort.  Of the included patients, 2675 (55.3%) had a f-Hb ≥10 
µg/g, and 705 (14.6%) patients had a f-Hb ≥400 µg/g.  
NHS Tayside included 1447 patients, of whom 92 (6.4%) were diagnosed with CRC.  There were 
684 males (47.3%) and 763 females (52.7%) with a median age of 66 years(IQR 55-75).  NHS 
Fife included 2082 patients, of whom 125 (6.0%) were diagnosed with CRC.  There were 958 
males (46.0%) and 1124 females (54.0%) with a median age of 65 years (IQR 54-75).  NHS 
Greater Glasgow and Clyde included 1312 patients, of whom 49 (3.7%) were diagnosed with 
CRC.  There were 567 males (43.2%) and 745 females (56.4%) with a median age of 60 years 
(IQR 49-70).  
Yield of CRC according to faecal haemoglobin concentration (f-Hb)
As the ranges of f-Hb studied increased, there was a reduction in the within-range NNS to detect 
CRC (Table 2).  Of the 2166 patient within the f-Hb range <10 µg/g, 14 (0.6%) were diagnosed 
with CRC, with a NNS of 155 within that f-Hb range.  Of the 705 patients with f-Hb ≥400 µg/g, 
158 (22.4%) were diagnosed with CRC with a NNS of 5 within that f-Hb range.
As the f-Hb thresholds related to the ranges studied increased, the trend was for a decrease in NNS 
to diagnose one CRC (Table 3).  Above the NICE DG30 suggested f-Hb threshold of  ≥10 µg/g, 
2675 colonoscopies were performed, and CRC diagnosed in 252 (9.4%), accounting for 94.7% of 
all CRC and giving a NNS of 11.  
Above a f-Hb threshold of ≥20 µg/g, 2135 colonoscopies were performed, and CRC diagnosed in 
242 (11.3%), accounting for 91.0% of all CRC and giving a NNS of 9.  
Above a f-Hb threshold of ≥100 µg/g, 1165 colonoscopies were performed, and CRC diagnosed in 
205 (17.6%), accounting for 77.1% of all CRC and giving a NNS of 6.   
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Yield of CRC according to f-Hb concentration by NHS board
In NHS Tayside, at the NICE DG30 suggested f-Hb threshold of  ≥10 µg/g, CRC was diagnosed 
in 84 patients, accounting for 91.3% of all CRC and giving a NNS of 9.  In NHS Fife, at the NICE 
DG30 suggested f-Hb threshold of  ≥10 µg/g, CRC was diagnosed in 122 patients, accounting for 
97.6% of all CRC and giving a NNS of 10.  In NHS GGC, at the NICE DG30 suggested f-Hb 
threshold of  ≥10 µg/g, CRC was diagnosed in 46 patients, accounting for 93.9% of all CRC and 
giving a NNS of 15.  
Characteristics of patients with f-Hb <10 µg/g diagnosed with CRC
Of the 14 patients diagnosed with CRC with a f-Hb <10 µg/g, nine were male and five were 
female (Table 4).  Only one patient was aged younger than 50 years (the age of first invite to the 
Scottish Bowel Screening Programme).  At the time of referral, 9 (64.3%) were found to be 
anaemic [18], of which 8 were iron deficient and the remaining patient had a pattern in keeping 
with anaemia of inflammation.  Furthermore, 8 patients diagnosed with CRC with a f-Hb <10 µg/g 
had a primary tumour location proximal to the splenic flexure.  Finally, three of these patients had 
polyp cancers.   
Discussion
This multi-centre retrospective observational study conducted across three Scottish NHS Boards 
demonstrates that FIT used in primary care as part of symptomatic lower GI symptom referral 
pathways can be used to appropriately guide further investigation, regardless of the “urgency” of 
the referral.   
Here, we report the colonoscopy findings in 4841 patients referred with “low” and “high risk” 
symptoms but who had all completed a FIT in primary care.  Of 2166 patients with f-Hb <10 µg/g, 
only 14 were diagnosed with CRC (0.6%), requiring 155 colonoscopies to detect one CRC (a NNS 
of 155).  In contrast, of the 2675 patients with f-Hb ≥10 µg/g, 252 (9.4%) had CRC, accounting 
for 94.7% of all CRC and giving an NNS of 11.  Although 6.3% of CRC was diagnosed in those 
with f-Hb <10 µg/g, this compares favourably to colonoscopy alone, with 6.5% of all patients who A
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had undergone colonoscopy in England in 2013 being diagnosed with CRC within three years of 
the index procedure [19].  
Previous studies have reported using detectable f-Hb, usually 2 or 4 µg/g, as a threshold for further 
investigation [15-16].  Indeed, the LoD of the HM-JACKarc FIT system used in the present study 
is 2 µg/g.  However, the NHS Tayside Department of Blood Science and NHS Greater Glasgow 
and Clyde Department of Clinical Biochemistry do not routinely quantitate f-Hb below the LoQ of 
7 µg/g due to the associated measurement imprecision below this concentration.  Additionally, 
values below 9 µg/g are not reported to clinicians in NHS GGC since they do not currently form 
part of any clinical guidance, pathway or framework.
It  has also been proposed that,  higher f-Hb thresholds be used to guide referral for investigation 
of symptomatic patients during the COVID pandemic and recovery phases.  In the present study, 
however, a modest increase in the f-Hb threshold to 20 µg/g resulted in a 9% rate of undetected  
CRC.  Alternatively, an additional higher threshold might be considered to allow triage of 
investigation urgency.  The recent guidance issued by the Scottish Government recommends that 
whilst patients with f-Hb ≥10 µg/g are referred for further investigation, those with f-Hb ≥400 
µg/g should undergo highest priority investigation, including colonoscopy and alternatives to 
colonoscopy such as computed tomography (CT) of abdomen and pelvis or colon capsule 
endoscopy (CCE) where available, during the COVID-19 pandemic and recovery periods [12].  
This very high-risk subgroup of patients with f-Hb ≥400 µg/g (15.4% of patients in the presented 
data in this study) had a NNS of 5 to detect one CRC. 
The diagnostic yield of colonoscopy for CRC in the present study at higher f-Hb thresholds 
(18.9% at f-Hb ≥150 µg/g)  is lower than that reported in studies from Nottingham [14, 16] 
(30.9% CRC at f-Hb ≥150 µg/g) and in the upcoming NICE FIT study (unpublished data). 
However, those studies included a high proportion of patients with high risk symptoms or who 
were referred along “2 ww” pathways.  In contrast the present study included patients referred 
from primary care at all levels of urgency. 
This study has a number of limitations.  The data were collected from three Scottish NHS Boards 
each with slight differences in their primary care referral pathways.  The data do not capture those 
patients who submitted a FIT and then either were not referred from primary care or did not A
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undergo colonoscopy.  This could include patients who did attend secondary care and were 
discharged without colonoscopy, or those investigated via other modalities such as CT with or 
without osmotic bowel preparation and pneumocolon.  Therefore, patients with f-Hb <10 µg/g in 
this study are likely to represent a higher-risk group than those patients with f-Hb <10 µg/g who 
were either not referred or did not undergo colonoscopy.  Furthermore, due to the retrospective 
nature of the study, patient level symptom data were not available, and therefore no association 
can be drawn between these and f-Hb or the diagnostic yield of CRC.  In addition, other factors 
recognised to influence both f-Hb at the diagnostic likelihood of SBD, including age, sex, and 
deprivation were not considered in the analysis [21-23].  Finally, the study did not include patients 
with other SBD.  This was in part due to the perceived prioritisation of CRC detection in the 
present COVID-19 pandemic and recovery phases, and also due to availability of more robust 
registration and data relating to CRC across all three NHS Boards.
However, the strengths of the presented data include large numbers of patients investigated by the 
“gold standard” investigation in the diagnosis of CRC.  These data were collected by each NHS 
Board following the introduction of FIT into symptomatic referral pathways so can be regarded as 
“real world” data.  In addition, this study is one of the few to include patients referred at all level 
of urgency.  In this study, only the first submitted valid f-Hb result was recorded and therefore no 
comment can be made on the possible use of multiple simultaneous or time distanced repeated f-
Hb estimations in patients with ongoing or recurrent symptoms.  Limited evidence does exist in 
these areas in screening and symptomatic cohorts [24], but further work is required before the 
impact of changes in f-Hb on diagnostic likelihood can be described in CRC.  Further, the FIT 
analytical systems used in the two laboratories were the same (HM-JACKarc), allowing pooling of 
data. This is an important consideration since different systems give different numerical estimates 
of f-Hb, and therefore data generated using the threshold of 10 µg/g as measured in this study may 
not be equivalent to that measured by other systems included in DG30 guidance, including OC 
Sensor and FOB Gold [25].
Finally, the presented characteristics of patients diagnosed with CRC with f-Hb <10 µg/g can be 
used to inform the very important issue of “safety netting”, in other words how to identify patients 
with low f-Hb who should go on to further investigation.  Anaemia and significant weight loss, 
both of which would often generate referral to secondary care even without the presence of lower 
GI symptoms, were prevalent amongst those with CRC and f-Hb <10 µg/g; however, further A
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studies are needed to confirm these associations and determine their clinical utility.  In addition, 
symptomatic patients with low f-Hb should be kept under observation until their symptoms have 
abated and GP must not be discouraged from referring such patients if they have severe and/or 
persistent symptoms.
In summary, the results of this study add to the ample evidence in the literature that low f-Hb 
identifies a group of symptomatic patients at very low risk of CRC and SBD, and that high f-Hb 
identifies a high-risk group.  Not only that, f-Hb estimation clearly outperforms symptoms as a 
predictor of CRC and SBD, even in those with “red flag” symptoms including rectal bleeding [26].  
It can therefore be stated with confidence that reliance should not be placed on specific symptoms 
or symptom complexes when deciding who to refer for colonoscopy. Symptoms should be 
regarded as an entry point to the diagnostic pathway and decision making on investigations should 
be guided by f-Hb.  Symptomatic patients with f-Hb <10 µg/g are very unlikely to be diagnosed 
with CRC and should not undergo investigation for this purpose without very good reason [12].  
Furthermore, higher f-Hb should be used to triage the modality and urgency of investigation for 
possible CRC in symptomatic patients.  Such an approach will be required during the COVID-19 
recovery period, during which access to colonoscopy is likely to remain limited, but also should be 
considered for use in the longer term to reduce the burden of over-investigation for both patients, 
and for stretched endoscopy resources.  Indeed, failure to implement this is likely to delay 
diagnosis of CRC due to dilution of the pool of referred patients who have CRC into a larger 
referral cohort that cannot be investigated in a timely fashion due to the capacity limitations of the 
NHS.
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Tables and footnotes
Table 1: Demographic characteristics of cohorts of patients undergoing colonoscopy after submitting a 
faecal immunochemical test (FIT) as part of symptomatic referral pathways in NHS Tayside, NHS Fife and 
NHS Greater Glasgow and Clyde (GGC), 
Region NHS Tayside NHS Fife NHS GGC
Total n 1447 2082 1312
CRC n (%) 92 (6.4) 125 (6.0) 49 (3.7)
Sex Male, n (%) 684 (47.3) 958 (46.0) 567 (43.2)
Female, n (%) 763 (52.7) 1124 (54.0) 745 (56.4)
Age years, median (IQR) 66 (55-75) 65 (54-75) 60 (49-70)
CRC: colorectal cancer, GGC: Greater Glasgow and Clyde, IQR: interquartile range
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Table 2: Colonoscopies and colorectal cancer (CRC) diagnoses made per given faecal 
haemoglobin concentration (f-Hb) ranges (µg/g) ) in symptomatic patients using a faecal 
immunochemical test (FIT and number needed to scope (NNS) to detect one CRC in that range
f-Hb range (µg/g) Colonoscopies 
performed within f-Hb 
range (n)
CRC diagnosed within 
f-Hb range (n)
NNS within f-Hb 
range (n)
All 4841 266 19
<10 2166 14 155
10-19 540 10 54
20-49 609 22 28
50-99 361 15 25
100-149 150 13 12
150-199 94 4 24
200-249 63 7 9
250-299 63 5 13
300-349 41 7 6
350-399 49 11 5
≥400 705 158 5
CRC: colorectal cancer, f-Hb: faecal haemoglobin concentration, NNS: number needed to scope to 
detect one CRC
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Table 3: Diagnostic yield of faecal haemoglobin concentration (f-Hb, µg/g) above threshold values 
(µg/g) to diagnose colorectal cancer (CRC) in symptomatic patients using a faecal 
immunochemical test (FIT) and number needed to scope to detect one CRC (NNS) 
f-Hb threshold (µg/g) Proportion of colonoscopies 
required (%)
Proportion of CRC 
diagnosed (%)
NNS (n)
10 55.3 94.7 11
20 44.1 91.0 9
50 31.5 82.7 7
100 24.1 77.1 6
150 21.0 72.2 6
200 19.0 70.7 5
250 17.7 68.0 5
300 16.4 66.2 5
350 15.6 63.5 5
400 14.6 59.4 5
CRC colorectal cancer, f-Hb: faecal haemoglobin concentration, NNS: number needed to scope to 
detect one CRC
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Table 4: Characteristics of symptomatic patients diagnosed with colorectal cancer (CRC) with 
faecal haemoglobin concentration  <10 µg/g by a faecal immunochemical Test (FIT) 
Age 
(years)
Sex Symptoms Blood Hb 
(mg/L)
CRC size 
(mm)
Primary CRC 
site
TNM 
stage
89 M Anaemia
Diarrhoea
71 17 Transverse 
colon
I 
54 F Diarrhoea 150 30 Rectum I 
78 M Anaemia
Change in bowel habit
120 26 Ascending 
colon
I
74 F Anaemia
Diarrhoea
102 60 Caecum NA
58 M Rectal bleeding 134 NA NA NA
87 F Anaemia 108 28 Caecum I 
66 M Anaemia
Change in bowel habit
94 57 Transverse 
colon
II
67 M Weight loss
Change in bowel habit
162 32 Transverse 
colon
IV
85 M Anaemia
Rectal mass (palpable)
122 35 Rectum I
68 F Anaemia
Change in bowel habit
95 NA Transverse 
colon
IV
69 M Anaemia
Weight loss
94 120 Caecum III
59 M Anaemia 122 50 Descending 
colon
II
39 M Change in bowel habit 152 25 Sigmoid colon II
66 F Change in bowel habit 144 14 Sigmoid colon II
CRC: colorectal cancer, F female, Hb: haemoglobin, M: male, NA not available, TNM: tumour, 
node, metastases
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